Linked Life Data

2190565

Source:http://linkedlifedata.com/resource/pubmed/id/2190565

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1990-7-12
pubmed:abstractText
The ability of glycosaminoglycans to bind to a wide number of biologically active macromolecules has already been investigated. Recent clinical trials on the possible therapeutic benefits of glycosaminoglycans must be placed in perspective, even if they appear to be particularly encouraging, especially as regards the glycosaminoglycan effects on certain coagulation factors. A multicenter, medium-term, double-blind, crossover trial was performed by several Italian Lipid Clinics to determine whether administration of a medium molecular weight glycosaminoglycan (Sulodexide) has a significant clinical effect. Patients affected by peripheral vascular disease and/or hyperlipidemia (type IIa, IIb and IV) were submitted to a 4-week wash-out period, followed by parenteral Sulodexide (S) or placebo (P) administration for 2 weeks, another 2 week wash-out period, parenteral crossover drug or P administration for 2 weeks and, finally, oral S administration for 6 months. Sulodexide lowered plasma viscosity and plasma fibrinogen in all patients. There was also a drop in triglycerides together with a rise in apo A-I and HDL-C in type IV hyperlipoproteinemics, whereas there was no significant effect on total or LDL-plasma cholesterol in type IIa and IIb patients. Moreover, there was a percent increase in peak flow and rest flow in the lower limbs of peripheral vascular disease patients. No side effects or intolerance phenomena were detected. The results indicate that Sulodexide administration may be useful in long-term treatment of patients with peripheral vascular disease and a concomitant increase in plasma triglycerides and/or fibrinogen and/or viscosity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0021-9150
pubmed:author
pubmed:issnType
Print
pubmed:volume
81
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
233-43
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:2190565-Adult, pubmed-meshheading:2190565-Aged, pubmed-meshheading:2190565-Blood Viscosity, pubmed-meshheading:2190565-Cholesterol, pubmed-meshheading:2190565-Clinical Trials as Topic, pubmed-meshheading:2190565-Double-Blind Method, pubmed-meshheading:2190565-Erythrocyte Deformability, pubmed-meshheading:2190565-Female, pubmed-meshheading:2190565-Fibrinogen, pubmed-meshheading:2190565-Glycosaminoglycans, pubmed-meshheading:2190565-Humans, pubmed-meshheading:2190565-Hyperlipidemias, pubmed-meshheading:2190565-Hyperlipoproteinemia Type II, pubmed-meshheading:2190565-Hyperlipoproteinemia Type V, pubmed-meshheading:2190565-Hypertriglyceridemia, pubmed-meshheading:2190565-Hypolipidemic Agents, pubmed-meshheading:2190565-Lipoproteins, pubmed-meshheading:2190565-Male, pubmed-meshheading:2190565-Middle Aged, pubmed-meshheading:2190565-Multicenter Studies as Topic, pubmed-meshheading:2190565-Triglycerides
pubmed:year
1990
pubmed:articleTitle
Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use.
pubmed:affiliation
Cattedra di Patologia Medica I, Università di Padova, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Multicenter Study